These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 29339642

  • 1. Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.
    Muta T, Miyamoto T, Kamimura T, Kanda Y, Nohgawa M, Ueda Y, Iwato K, Sasaki O, Mori T, Uchida N, Iida S, Fukuda T, Atsuta Y, Sunami K.
    Acta Haematol; 2018; 139(1):35-44. PubMed ID: 29339642
    [Abstract] [Full Text] [Related]

  • 2. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group.
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [Abstract] [Full Text] [Related]

  • 3. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
    Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relapsed multiple myeloma: who benefits from salvage autografts?
    Chow AW, Lee CH, Hiwase DK, To LB, Horvath N.
    Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
    [Abstract] [Full Text] [Related]

  • 6. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, Chen C, Kukreti V, Reece DE.
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [Abstract] [Full Text] [Related]

  • 7. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H.
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. When to recommend a second autograft in patients with relapsed myeloma?
    Ziogas DC, Terpos E, Dimopoulos MA.
    Leuk Lymphoma; 2017 Apr; 58(4):781-787. PubMed ID: 27894207
    [Abstract] [Full Text] [Related]

  • 10. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J, Dickinson M, Voskoboynik M, Collins M, Ritchie D, Toner G.
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [Abstract] [Full Text] [Related]

  • 11. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
    Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K, German Myeloma Multicenter Group (GMMG).
    Leukemia; 2021 Apr; 35(4):1134-1144. PubMed ID: 32694619
    [Abstract] [Full Text] [Related]

  • 12. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [Abstract] [Full Text] [Related]

  • 13. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
    Gössi U, Jeker B, Mansouri Taleghani B, Bacher U, Novak U, Betticher D, Egger T, Zander T, Pabst T.
    Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
    [Abstract] [Full Text] [Related]

  • 14. Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes.
    Kumar L, Gundu N, Kancharia H, Sahoo RK, Malik PS, Sharma A, Gupta R, Sharma O, Biswas A, Kumar R, Thulkar S, Mallick S, AIIMS Myeloma Group.
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):80-90.e5. PubMed ID: 33129746
    [Abstract] [Full Text] [Related]

  • 15. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 16. Second autologous transplant as salvage therapy in multiple myeloma.
    Atanackovic D, Schilling G.
    Br J Haematol; 2013 Dec; 163(5):565-72. PubMed ID: 24111632
    [Abstract] [Full Text] [Related]

  • 17. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of second salvage autologous transplantation in myeloma patients.
    Bicsko RR, Nyilas R, Szasz R, Varoczy L, Kiss A, Udvardy M, Illes A, Gergely L.
    Pathol Oncol Res; 2024 Sep; 30():1611851. PubMed ID: 39081461
    [Abstract] [Full Text] [Related]

  • 20. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
    Zannetti BA, Tacchetti P, Pantani L, Gamberi B, Tosi P, Rocchi S, Cellini C, Ronconi S, Pezzi A, Mancuso K, Rizzello I, Caratozzolo I, Martello M, Dozza L, Cavo M, Zamagni E.
    Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.